METHOD Intellectual performance was assessed for school performance, behaviour, and intelligence. Urinary glycosaminoglycans were quantified by mass spectrometry. IDS variants were analysed in expression studies for enzymatic activity and processing by immunoblotting.
ABBREVIATIONS
METHOD Intellectual performance was assessed for school performance, behaviour, and intelligence. Urinary glycosaminoglycans were quantified by mass spectrometry. IDS variants were analysed in expression studies for enzymatic activity and processing by immunoblotting.
RESULTS Six patients had a non-neuronopathic phenotype and 11 a neuronopathic phenotype, three of whom had epilepsy. Total deletion of IDS invariably resulted in the neuronopathic phenotype. Phenotypes of seven known IDS variants were consistent with the literature. Expression studies of nine variants were novel and showed impaired IDS enzymatic activity, aberrant intracellular processing, and elevated urinary excretion of heparan sulphate and dermatan sulphate irrespective of the MPS II phenotype.
INTERPRETATION
We speculate that very low or cell-type-specific IDS residual activity is sufficient to prevent the neuronal phenotype of MPS II. Whereas the molecular effects of IDS variants do not distinguish between MPS II phenotypes, the IDS genotype is a strong predictor.
Mucopolysaccharidosis type II (MPS type II; also called Hunter syndrome; Online Mendelian Inheritance in Man
[OMIM] 309900) is a monogenic lysosomal storage disorder caused by variants in the iduronate-2-sulphatase gene (IDS; NM_000202.6). The IDS gene encodes a lysosomal enzyme, and deficiency causes accumulation of the glycosaminoglycans (GAGs) heparan sulphate and dermatan sulphate in multiple organs. Clinical characteristics include abnormalities in the respiratory tract, central nervous system (CNS), cardiac valves, and the size of the liver and spleen. 1, 2 There are two major phenotypes with respect to CNS involvement. In the neuronopathic form, patients develop a progressive intellectual disability that becomes apparent at the age of 3 to 5 years. 3 These patients become completely dependent on care for basic needs, and have reduced life expectancy compared with those with the non-neuronopathic phenotype. 4 Brain abnormalities such as white matter lesions, Virchow-Robin spaces, and signs of atrophy can be seen on cerebral magnetic resonance imaging, 5 and patients have behavioural problems, in some cases epilepsy. 6 Patients with the non-neuronopathic form have no or minimal intellectual disability. This is despite mild abnormalities in the CNS including Virchow-Robin spaces, a reduced corpus callosum size, and a lack of agerelated increase in cortical white matter. 7 Enzyme replacement therapy (ERT) with recombinant IDS protein (Elaprase; Shire Human Genetic Therapies, Boston, MA, USA) has been available for patients with MPS II in Europe since 2007. ERT has been shown to normalize liver and spleen size, improve walking ability, and reduce GAG levels in urine. 8 However, owing to poor vascularization and cellular uptake, ERT is inefficient in certain tissues including cardiac valves, cartilage, and bone, and cannot pass the blood-brain barrier to treat CNS symptoms.
Over 580 variants in the X-linked IDS gene have been reported (http://www.hgmd.org). These are distributed over the entire gene and include missense, nonsense, and splicing variants, small and large deletions, and rearrangements with the IDS pseudogene. About 25% of IDS variants have been estimated to be de novo, as determined by sequence analysis of 102 mothers of MPS II. 9 Patients in whom the entire IDS gene is deleted have been reported with the neuronopathic phenotype. 10 Expression studies of a total of 24 variants have been reported in six studies. [11] [12] [13] [14] [15] [16] However, given the small number of patients, the current understanding of the genotype-phenotype relationship in MPS II is incomplete. It is also poorly understood how the MPS II phenotype is reflected at the level of urinary GAGs (uGAGs). In this study, we analysed the genotype-phenotype relationship in all 17 patients with MPS II currently known in the Netherlands by combining clinical information with expression studies and mass spectrometry-based assay of uGAGs to investigate whether the molecular effects of IDS variants can predict the clinical phenotype.
METHOD
The study protocol was approved by the Medical Ethical Committee at Erasmus Medical Center, Rotterdam. All patients or their parents provided informed consent. Patients received ERT with recombinant iduronate-2-sulphatase 'Idursulfase' (Elaprase) at 0.5 mg/kg, by weekly infusion, except for patient 15 who remained untreated. The diagnosis was based on clinical features, IDS deficiency in leukocytes and/or fibroblasts, and the presence of a variant in the IDS gene. Genotypes were determined using Sanger sequencing of all IDS exons and multiplex ligation-dependent probe amplification (IDS P 164, MRC-Holland). The deletion of the entire IDS gene was mapped using single nucleotide polymorphism array. IDS gene variants analysed in our laboratory before 2010 or analysed in other laboratories were reconfirmed by sequence analysis of genomic DNA using NM_000202.6 as reference messenger RNA (mRNA). Splicing predictions were performed using Alamut Visual v.2.4.2 (Interactive Biosoftware, Rouen, France) as described. 17 Samples for biochemical analyses (fibroblasts and urine) were collected before the start of ERT.
For expression studies, the IDS complementary DNA (cDNA), cloned in pcDNA3, was transfected using polyethylenimine in HEK293 cells with pcDNA3-b-lactamase-myc as transfection control. IDS activity was measured using 4-methylumbelliferyl-a-L-iduronide-2-sulphate (MU-aIdoA-2S) (Moscerdam Substrates, Amsterdam, the Netherlands) based on the method of Voznyi et al. 18 Enzyme activities were corrected for total protein using the bicinchoninic acid assay (Pierce, Rockford, IL, USA). Immunoblot analysis was performed as described 19 using the following antibodies: anti-IDS (sc-365149; Santa Cruz Biotechnology, Dallas, TX, USA), anti-S6 (5G10; Santa Cruz Biotechnology), and anti-Myc (9B11; Cell Signaling Technology, Danvers, MA, USA).
The clinical phenotype of patients with MPS II (neuronopathic or non-neuronopathic) was based on the presence or absence of intellectual disability. As intravenously applied recombinant enzyme cannot pass the blood-brain barrier, the CNS phenotype is expected not to be altered by ERT, and classification of patients as non-neuronopathic or neuronopathic is considered to be independent of ERT efficacy. For all patients under 18 years of age, multiple Griffiths Mental Developmental Scales 20 results were available (data not shown). The severity of the intellectual disability was determined by two treating physicians on the basis of: (1) school performance and/or the level of education; (2) behaviour; and (3) IQ scores above or below 70. Data from the last visit were used. Normal level of education, behaviour, and aged-related Griffiths scores was scored as 'À'. A deviation on one of three scales resulted in a '+' for intellectual disability, with a maximum of '+++' for patients who performed at lowest educational level, showed strongly abnormal behaviour, and had Griffiths scores below 70. Epilepsy was scored as not present 'À'; a history of epilepsy but adequately controlled by medication '+'; or difficult to treat epilepsy '++'. Urine samples were collected and stored at À20°C. Total GAG levels were determined according to the method of de Jong et al. 21 The determination coefficient (R 2 ) for GAG measurements was calculated with GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Levels of dermatan sulphate and heparan sulphate were determined using methanolysis to degrade polysaccharides and quantification of disaccharides on the basis of the method of Zhang et al. 22 Dermatan sulphate-and heparan sulphatederived disaccharides were analysed using an AcquityQuattro Premier XE system (Waters, Milford, MA, USA), 22 and quantified using calibrators ranging from 0 to 63 lg. .01 m/z. Creatinine was determined enzymatically by a creatinine assay using a commercially available kit (Roche Modular P, Hague Road, Indianapolis, IN, USA) on an autoanalyser. A more detailed description of the methods is provided in Appendix S1 (online supporting information). Table I . All 17 patients diagnosed with MPS II and referred to our centre before April 2014 were included. Most patients were diagnosed between 0 years and 6 years. Ages at last clinical evaluation ranged from 5 to 51 years. Two patients were brothers (patients 3 and 4). All other patients were not related. Three patients (patients 8, 10, and 11) deceased at 21, 16, and 15 years of age (respectively) owing to disease-related cardiorespiratory failure. All patients, except patient 15, received ERT for a period of 1 to 15 years (mean 6y). Intellectual disability was severe in nine patients, intermediate in two patients, and not evident in six patients. Three of the patients with the neuronopathic phenotype also What this paper adds
RESULTS

Patient characteristics are shown in
• Central nervous system phenotypes of eight iduronate-2-sulphatase gene (IDS) variants are reported.
• Expression studies of nine IDS gene variants are reported.
• The molecular effects of IDS variants do not distinguish between mucopolysaccharidosis (MPS) II phenotypes.
• The IDS genotype is a good predictor of the neuronopathic and non-neuronopathic MPS II phenotype. The age of diagnosis was defined as the age at which the diagnosis was made based on enzyme activity. presented with epilepsy. Four patients (patients 1, 5, 9, and 17) were older than 21 years at last assessment and were among the patients who performed the best. IDS enzyme activities at baseline ranged from 0.01 to 0.56 nmol/4h/mg in fibroblasts (normal range 26-109 nmol/4h/mg) ( Table I) . These values were in most cases below the limit of detection of the assay (0.42 nmol/4h/mg), and it was therefore not possible to relate residual IDS enzyme activity to the MPS II phenotype. uGAGs in samples obtained before the start of ERT were analysed. Total uGAG levels were measured using dimethylmethylene blue (Fig. 1a) , and levels of individual heparan sulphate and dermatan sulphate using mass spectrometry (Fig. 1b) . In Figure 1 , the severity of intellectual disability is indicated by the size of the symbols. In all patients, the total uGAG, heparan sulphate, and dermatan sulphate levels were strongly elevated relative to normal values. The total uGAG levels correlated with age and followed an exponentially decreasing course (R 2 =0.92; Fig. 1a ). This was also the case for individual levels of heparan sulphate and dermatan sulphate (heparan sulphate R 2 =0.71; dermatan sulphate R 2 =0.49). The age-dependency of uGAG levels makes a statistical comparison between patients with a non-neuronopathic or neuronopathic phenotype impossible, since age is a strong confounder. However, comparison of individual patients at similar ages indicated that uGAG levels did not reflect disease severity: patients 3 and 4 were non-neuronopathic when assessed at the age of 7 years, but contained the highest heparan sulphate and dermatan sulphate levels compared with the neuronopathic patients 15 and 16 and the intermediate patient 7, who were assessed at the ages of 8, 8, and 5 respectively. Altogether, patients with both the non-neuronopathic and neuronopathic phenotypes were present in our cohort, and these groups could not be distinguished on the basis of IDS enzymatic activity in fibroblasts or by uGAG levels.
To examine the molecular effect of the IDS variants involved, we performed expression studies. In our cohort of 17 patients, 15 unique IDS variants were identified (13 within the IDS gene and two total IDS gene deletions), six of which to our knowledge have not been published before. In seven of the nine previously reported variants, information about the phenotype of the patient was reported, and in three of the nine variants molecular effects were reported (Table I) . 10, 13, [23] [24] [25] [26] [27] [28] The 15 variants from this study were spread across the entire IDS gene (Fig. S1 , online supporting information), and included eight missense variants, three small deletions, two total gene deletions, one nonsense variant, and one splice site variant (Table I) . IDS sequence information was available for six mothers of our patients, and this indicated that p.Phe137-Ser and the gross IDS deletion of patient 15 were de novo variants. This relatively high percentage is consistent with a previous report on 102 patients with MPS II. 9 It indicates that the IDS gene is susceptible to de novo mutation, and that this should be taken into account for genetic counselling. All missense and nonsense variants and small deletions were introduced in the IDS cDNA by site-directed mutagenesis, expressed in HEK293T cells, and the effects on intracellular processing and enzymatic activity were analysed. Immunoblot analysis using an IDS antibody showed that the wild-type IDS cDNA yielded three major products with apparent molecular masses of 76, 55, and 45 kilodaltons (kDa) 48 hours after transfection (Fig. 2) , consistent with previous reports on IDS processing. These have been identified to represent the following intracellular processing products: precursor, an intermediate form, and the mature form respectively. 29 In IDS enzyme activity assays, the transfected wild-type construct caused an activity of 470 nmol/mg/4h, which was 30-fold above background measured using cells transfected with an empty expression vector (16 nmol/mg/4h) (Fig. S2 , online supporting information). Results for IDS variants are listed below.
Missense variants
Seven of eight missense variants showed impairment of IDS protein processing to the 55 kDa and 45 kDa active forms (Fig. 2) . The p.Asp269Val variant failed to show detectable protein expression. Analysis by quantitative PCR with reverse transcription showed that the mutant mRNA was expressed to levels similar to that of wild-type mRNA, both when overexpressed in HEK293 cells (as reported previously 24 ) and when expressed endogenously in fibroblasts (data not shown). We speculate that the p.Asp269Val variant destabilizes the IDS protein, leading to protein degradation. All eight missense variants showed complete absence of IDS enzymatic activity (Fig. S2) .
Nonsense variants and small deletions
The p.Ser117del variant represented an in-frame deletion of one amino acid, and showed expression of the 76 kDa protein but absence of detectable further processing. While endogenous mRNA expression of nonsense variants and out-of-frame deletions is likely to be very low owing to mRNA degradation, we considered the possibility that low amounts of truncated protein may be expressed and cause residual IDS activity. The nonsense variant p.Glu459* led to the production of an IDS protein truncated by 91 amino acids (14 kDa). A single 62 kDa band was observed by immunoblot analysis, consistent with the formation of a precursor protein of 76 kDa truncated by 14 kDa and the absence of proteolytic cleavage to truncated counterparts of the 55 kDa and 45 kDa forms. The p.Leu182Cysfs*31 variant resulted in a truncation by 416 amino acids (52 kDa), which would result in a predicted precursor of 24 kDa. No protein product was detected by immunoblot analysis, which may either have been caused by the absence of an epitope that could be recognized by our antibody, or by protein degradation. The p.Gly504Alafs*8 variant was truncated by 40 amino acids (5 kDa), resulting in a predicted precursor protein with a molecular mass of 71 kDa. However, the observed protein was slightly shorter, with an apparent molecular mass of 65 kDa, possibly caused by additional proteolytic cleavage. Also in this case, no truncated counterparts of normal proteolytic processing were observed. All four variants in this category showed complete absence of detectable IDS enzymatic activity, similar to the missense variants expressed in this study (Fig. S2) .
DISCUSSION
We have analysed the genotype-phenotype relationship for 17 patients with MPS II and performed expression studies for 12 variants, nine of which have not been reported previously. Expression studies of a total of 24 variants have been published so far, bringing the total number of variants analysed and described in the literature so far to 33.
Variants that cause a neuronopathic phenotype
Over 580 IDS variants have been reported, and clinical information is available for several of these. In many cases, a similar phenotype has been reported for the same variants with respect to CNS involvement, although no uniform definition for the severity of the MPS II phenotype has been used in the literature. The most extreme case, deletion of the entire IDS gene, invariably results in the neuronopathic phenotype, 10 including patients 15 and 16 from this study. Patient 15 contained an IDS deletion of 1.4 megabases that also included the AFF2 gene and in addition a gain on 4q12 and a loss on 6p21.1; in patient 16 the deletion was 1.1 megabases at a more 5 0 location in which the AFF2 gene was intact. This strengthens the conclusion that the CNS phenotype in patients with MPS II is primarily caused by the IDS gene.
Besides the two patients with total IDS gene deletions, nine patients in our cohort with eight different IDS variants also showed intellectual disability. Two of these variants, the missense variants p.Pro86Leu and the small deletion p.Ser117del, have been reported previously to be associated with severe intellectual disability in patients with distinct MPS II. 16, 24, 27 This suggests that these variants are predictive for a neuronopathic phenotype, which should be confirmed in further studies. The missense variant p.Ser333Leu is one of the most common variants. It has been associated with a neuronopathic phenotype 14, 23 but also once with an intermediate phenotype in a 7-year-old patient reported previously. 28 This is similar to the observations in the present study, since patient 6 had a neuronopathic phenotype at the age of 14 and patient 7 had an intermediate phenotype at the age of 5. It should be noted, however, that the latter patient was still relatively young and that progressive decline of intellectual performance may become more evident later in life. The molecular effects of five variants in patients with the neuronopathic phenotype has not been reported previously. These include the missense variants p.Ser349Arg and p.Glu521Lys, the nonsense variant p.Glu459*, and the small deletions p.Leu182Cysfs*31 and p.Gly504Alafs*4.
Variants that cause a non-neuronopathic phenotype
Only six patients with five different IDS variants showed no intellectual disability, indicating that these are associated with a non-neuronopathic phenotype. Three of these variants, including the missense variants p.Asp269Val and p.Cys422Tyr, and the splicing variant p.Gly374Gly (c.1122C>T), have been reported previously, and the corresponding patients also showed a non-neuronopathic phenotype similar to the patients in this study. 23, 24 The phenotypes of two variants, p.Ser61Tyr and p.Phe137Ser, have not been reported previously, and were found to be associated with a non-neuronopathic phenotype in the present study. Longer follow-up is required to determine the outcome of the p.Phe137Ser IDS variant on the MPS II phenotype, as the patients involved were assessed at the age of 7 years.
uGAGs: lack of correlation with the phenotype A long-standing assay for uGAGs is the dimethylmethylene blue assay, a test that quantifies total GAGs, which has the disadvantage of limited sensitivity and specificity. Mass spectrometry-based methods represent an important improvement, as these have higher sensitivity and can unambiguously identify individual GAGs. These studies showed that GAG levels in urine are invariably elevated in patients with confirmed MPS. However, the relationship between u n t r a n s f e c t e d uGAG excretion and MPS II phenotype is still unexplored. Our results suggest that levels of urinary heparan sulphate and dermatan sulphate do not predict the neuronopathic or non-neuronopathic MPS II phenotype. Further studies are required to investigate why this is, and which biomarkers are more suitable for phenotype prediction.
Expression analysis
No differences in enzymatic activity were observed between variants associated with the non-neuronopathic or the neuronopathic forms of the disease. Previous expression studies of 24 pathogenic IDS variants also failed to show a correlation with MPS II phenotype. 12, 13, 15, 16 There are several possible explanations for this finding. One could argue that IDS enzymatic activity is not the only factor responsible for MPS II symptoms, and that additional, yet unidentified, modifying factors exist that determine whether the CNS is affected to cause intellectual disability. A second, not necessarily exclusive, possibility is that a very small residual IDS activity is sufficient to relieve CNS symptoms, and that the IDS activity levels may be celltype-dependent. This difference in residual activity may be too small to be detected using the current in vitro assay for IDS activity in fibroblasts, or it may only be detectable in neuronal cells. Future studies are required to test these possibilities.
Currently it is unclear why all variants in this study have strongly impaired intracellular processing. Correct intracellular processing is associated with the targeting of the IDS protein to the lysosome. Normally, the 73 kDa to 78 kDa precursor is phosphorylated to a 90 kDa protein, which is then cleaved to 55 kDa and 45 kDa forms that are active in the lysosome. 29 All variants expressed in this study showed impairment of processing towards the forms known to be active in the lysosome. However, impaired processing alone cannot explain the lack of enzymatic activity of mutant IDS, as unprocessed IDS protein, such as recombinant IDS protein (Elaprase), has enzymatic activity in vitro. Future studies should aim to investigate further the relationship between the CNS phenotype, IDS enzymatic activity, and intracellular processing, preferably including different cell types (e.g. neuronal cells), and the use of modified enzyme assays with increased sensitivity.
Genotype as the most reliable way to predict phenotype
The lack of predictive power of the molecular effects for clinical phenotype has been demonstrated in this study. Is there another way to predict the MPS II phenotype? We noticed a remarkable concordance for the clinical effects of IDS variants in different patients: besides the total gene deletions, all six variants (three neuronopathic [p.Pro86-Leu, p.Ser117del, p.Ser333Leu] and three non-neuronopathic [p.Asp269Val, p.Cys422Tyr, and the splicing variant c.1122C>T]) for which the clinical phenotype has been described in the literature showed a similar phenotype in this study. Our study contained two brothers (patients 3 and 4) with an identical genotype and a non-neuronopathic phenotype. The p.Ser333Leu was present in two unrelated patients (6 and 7), and these showed a CNS phenotype in both cases. These findings further stress the clinical importance of the genotype-phenotype relationship in MPS II because the genotype has strong predictive power. editing the manuscript. Femke A T de Vries for SNP array analysis. The authors have stated that they had no interest that could be perceived as posing a conflict or bias.
SUPPORTING INFORMATION
The following additional material may be found online:
Appendix S1: Methods. Figure S1 : Location of variants in the iduronate-2-sulphatase (IDS) protein. Exons are numbered. The coloured boxes represent the peptides formed during processing: blue, signal peptide; green, propeptide; grey, core peptide; yellow, carboxyl terminus. ▼, missense variant; ■, nonsense variant; 9, deletion. 
